Bringing the fundamentals into focus…
Back to Niagen Bioscience, Inc.
How Niagen Bioscience, Inc. stacks up
NAGE · against 158 other Consumer Defensive companies of similar size
Valuation
55/ 100
Below the middle of the pack.
Ranked #82 of 159 · scores higher than 48% of peers
Bars: peers in each 10-point band of the valuation score13 peers with a valuation score of 50–59, including NAGE · Click a bar to see the companies
Why valuation scores 55?
Weighted metrics compared with all Consumer Defensive companies.A mix: stronger earnings yield, but weaker free cash flow yield than most Consumer Defensive peers.
- less free cash flow for the price paid: weaker than 73% of peers. Free cash flow yield: 3.0% vs peer median 6.2%
- EBITDA yield is close to the peer norm. EBITDA yield: 7.8% vs peer median 8.7%
- higher earnings for the price paid: stronger than 78% of peers. Earnings yield: 8.6% vs peer median 4.5%
Metric by metric
Position: dot = NAGE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NAGE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 147 reported | 8.1% | 4.7% | 71% | 30% | |
| EBITDA yieldHigher is better · 165 reported | 7.8% | 10.4% | 40% | 50% | |
| Free cash flow yieldHigher is better · 73 reported | 3.0% | 6.6% | 36% | 20% | |
| Book yieldHigher is better · 152 reported | 44.2% | 88.3% | 26% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around NAGEScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score